111 results about "Renal tissue" patented technology

The invention discloses application of oligopeptide in preparation of a medicine for treating and / or preventing diabetic nephropathy. The oligopeptides comprise oligopeptides with the amino acid sequence of SEQ ID NO: 1: LNLYP and derivative sequences or conservative substitution variants of the oligopeptides. The oligopeptide can significantly improve renal function indexes of mice with diabetic nephropathy, such as UACR, serum creatinine, urea nitrogen and the like, enhance podocyte barrier integrity and inhibit accumulation of advanced glycosylation end products AGEs in kidney tissues, and provides a basis for development of novel drugs for treating diabetic nephropathy.

The present invention belongs to the field of traditional Chinese medicines, and particularly relates to Leixihaokang, a preparation method therefor, and use thereof. The Leixihaokang of the present invention is prepared from the following active pharmaceutical ingredients in parts by weight: 10 parts of Tripterygium glycosides and 0.1-1.3 parts of Artemisia annua extract. According to the present invention, animal experiments prove that the Leixihaokang can ameliorate renal damage in nephrotic syndrome caused by adriamycin, reduce the occurrence of proteinuria, and reduce the apoptosis of renal tissue cells. Meanwhile, the Leixihaokang of the present invention has a good inhibitory effect on renal, hepatic, splenic, and cardiac toxicity in the treatment process of nephrotic syndrome. According to the present invention, animal experiments also prove that the Leixihaokang can ameliorate skin injury in imiquimod-induced psoriasis, reduce inflammatory infiltration and alleviate skin damage. Meanwhile, the Leixihaokang has a certain degree of inhibitory effect on the hepatic and reproductive system toxicity in the treatment process of psoriasis.

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.

Apparatus, systems, and methods provide access to the renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances to ablate a thin layer of tissue lining at least a portion of the renal pelvis to disrupt renal nerves within the tissue lining of the renal pelvis.

The invention belongs to the technical field of biological medicine, and particularly relates to an in-vitro fusion technology for multi-lineage human kidney organs and application thereof. The invention provides a method for realizing culture of multilineage kidney organs by fusing kidney units and ureteral bud organs in vitro. According to the in-vitro fusion technology of the kidney organoid reported by the invention, two organoid with different pedigree sources, namely the kidney unit and the ureteral bud, can be efficiently fused, a UB tubular structure is integrated into the kidney unit organoid, and the UB tubular structure starts from a single ureteral bud and is wrapped by kidney unit precursor cells in a similar in-vivo development process, and finally develops into a kidney with glomerulus and a plurality of kidney cells. The multi-lineage renal organ comprises a catheter, a proximal tube, a marrow tab thin section, a distal tube, a connecting tube and a ureteral bud with a single outlet. A framework is provided for an engineered renal unit and a smooth collection system, and the method is an important step for generating the functional renal tissue from the beginning.

The application discloses a marker for determining the severity of IgAN kidney tissue lesions and application thereof, and inventors find that ACTN4, ACADS and COL1A1 are significantly differentially expressed proteins in kidney tissues. The significant down-regulation of ACTN4 may cause the change of actin cytoskeleton of IgAN glomerular podocytes; the significant down-regulation of ACAD may indirectly participate in the occurrence process of abnormal structure and function of IgAN renal tubular epithelial cells by affecting fatty acid metabolism in the cells; and the significant up-regulation of COL1A1 may participate in the accumulation of extracellular matrix in the renal interstitium of IgAN, and play a certain role in promoting the renal interstitial fibrosis. The combination of ACTN4, ACADS and COL1A1 has good prediction efficiency for the diagnosis of the severity of IgAN kidney tissue lesions, and the area under the ROC curve is 0.815, P 0.043. In addition, the immunohistochemical results also confirm the expression trend of the three proteins ACTN4, ACADS and COL1A1 in the corresponding kidney tissue substructures in proteomics.

This invention provides the application of dehydrouncitonin in the preparation of drugs that reduce polymyxin toxicity, belonging to the field of pharmaceutical technology. This invention uses dehydrouncitonin in combination with polymyxin. The combined use of dehydrouncitonin and polymyxin E increased the viability of HEK293T and RAW264.7 cells to 87.7% and 94.3%, respectively, with highly significant differences compared to the control, indicating that treatment with dehydrouncitonin in combination with polymyxin E can significantly inhibit the cytotoxic effect of polymyxin E. This invention uses a mouse model to demonstrate that treatment with dehydrouncitonin in combination with polymyxin E can significantly reduce the neurotoxicity and nephrotoxicity of polymyxin E alone in mice, specifically manifested in improved neurobehavioral effects and improved histopathological effects on brain and kidney tissues. This invention uses dehydrouncitonin in combination with polymyxin E to significantly inhibit the cytotoxic, neurotoxic, and nephrotoxic effects of polymyxin E.

The invention discloses a novel application of elsholtzia rugulosa extract in preparation of a medicine for preventing and treating acute kidney injury, and belongs to the technical field of biology. The medicine is applied to prevention and / or treatment of acute kidney injury, the content of urea nitrogen (BUN) in plasma can be reduced, pathological injury of kidney tissue is improved, and expression of related factors in the kidney tissue is adjusted; the elsholtzia rugulosa extract can effectively reduce the content of BUN in plasma of a cis-platinum (CDDP)-induced acute kidney injury model mouse, effectively improve pathological injury of kidney tissue of the cis-platinum-induced acute kidney injury model mouse and regulate expression of related factors in the kidney tissue of the cis-platinum-induced acute kidney injury model mouse under a relatively low dosage. The raw materials come from natural products and are convenient to collect and high in safety.

The application relates to an application of a drug for preventing and treating deafness in preparation of a drug for preventing and treating acute kidney injury caused by cisplatin, wherein the effective component of the drug for preventing and treating acute kidney injury caused by cisplatin is prepared from raw medicinal materials in the following weight percentage: 27-33% of ginseng, 16-20% of astragalus, 16-20% of pueraria, 11-13% of curcuma, 12-15% of platycodon, and 8-10% of licorice. The drug for preventing and treating acute kidney injury caused by cisplatin in the application can obviously reduce the creatinine and urea nitrogen levels, improve the morphological damage of kidney tissues, and has a remarkable effect on preventing and treating acute kidney injury caused by cisplatin.

The invention belongs to the technical field of biological medicines, and particularly relates to a traditional Chinese medicine composition for treating chronic renal failure of pets and a liposome and application thereof. According to the traditional Chinese medicine composition provided by the invention, by virtue of turmeric, eucommia ulmoides, medlar, astragalus membranaceus, poria cocos and beta-sitosterol, the aim of synergistically treating the renal failure in the aspects of resisting inflammation, inhibiting renal fibrosis, improving a glomerular filtration function, promoting kidney cell repair and the like can be achieved, and a new solution is provided for effectively treating the chronic renal failure of pets. The traditional Chinese medicine composition disclosed by the invention has a good recovery effect on kidney tissues of pets with chronic renal failure, can effectively reduce urea nitrogen and creatinine levels of blood of the pets with chronic renal failure, relieves renal failure symptoms, and has a good treatment effect; the liposome disclosed by the invention has the advantages of high effective rate, high cure rate and quick effect, and the treatment effect of the liposome is superior to that of a third-stage clinical medicine, namely beraprost, for treating the kidney renal failure of pets in the current market.

The invention discloses an application of PARP1PROTACA19 in preparation of a medicine for preventing and treating acute kidney injury, and relates to the technical field of medicines, and the key points of the technical scheme are as follows: PARP1PROTAC A19 can reduce the expression level of PARP1 in HK2 cells and mice, reduce the levels of acute kidney injury markers KIM-1 and inflammatory factors of the HK2 cells and the mice, improve pathological changes of kidney tissues, and inhibit the occurrence of acute kidney injury. The traditional Chinese medicine composition has obvious prevention and treatment effects on acute kidney injury.

The invention discloses a diabetic nephropathy marker PARP1, a primer combination and application, and relates to the technical field of biology. The sequence of the primer combination is PARP1-F, and is as shown in SEQ ID NO. 1; 1, PARP1-R as shown in SEQ ID NO. 2; an internal reference primer beta-actin-F, which is as shown in SEQ ID NO. 17; an internal reference primer beta-actin-R is as shown in SEQ ID NO. 18. The invention finds that the expression of PARP1 in the kidney tissue of a patient with diabetic nephropathy is increased and is positively correlated with ACR (Activated Receptor). The invention also finds that PARP1 is related to podocyte damage, and knocking down PARP1 can relieve podocyte endoplasmic reticulum stress and apoptosis, and can reflect the progress of DKD to a certain extent.

The application discloses a biomarker for diagnosing diabetic nephropathy and application thereof, and relates to the technical field of biological medicine. The biomarker for diagnosing diabetic nephropathy comprises urine MBP-1 or urine MBP-1 / urine creatinine. The urine MBP-1 or urine MBP-1 / urine creatinine biomarker has high identification efficiency: when the urine MBP-1 or urine MBP-1 / urine creatinine ratio is used for identifying DKD and NDRD, the area under the ROC curve (AUC) reaches 0.899, the sensitivity and the specificity are both higher than 0.85, and the two diseases can be efficiently distinguished. The method is non-invasive and convenient: only urine samples need to be collected, the risk of complications such as bleeding and infection caused by invasive operations such as kidney biopsy is avoided, the patient has high acceptance, repeated detection can be performed to dynamically track the disease condition, and special equipment is not needed, so that the method is convenient for clinical popularization and application. Through kidney tissue immunofluorescence verification, MBP-1 is deposited in a large amount in the glomerulus of DKD and is not deposited in NDRD, and thus the kidney local pathological change can be directly reflected.

The application belongs to the field of biological medicine, and provides application of miR-152 as a target in preparation of a drug for treating podocytopathy and the drug. Specifically, the application relates to application of miR-152 as a therapeutic target and / or a drug screening target in preparation of a drug for treating podocytopathy and a drug for treating FSGS nephropathy. The miR-152 inhibitor can inhibit high expression of miR-152 in kidney tissues of podocytopathy or FSGS nephropathy, inhibit down-regulation of synaptopodin protein, RhoA protein and 14-3-3 beta protein expression, protect stability of a cytoskeleton of a podocyte in kidney tissues, and delay progressive development of FSGS disease. The application provides a new therapeutic target for treatment of FSGS disease, and has important social and economic significance.

The present invention belongs to the field of biomedical technology and specifically discloses the use of a substance that inhibits the activity and / or expression of a CAPG gene or protein in preparing a product for treating renal fibrosis caused by renal injury. The present invention first discovered through research that CAPG is expressed at a low level in normal renal tissue, but its expression level is elevated in renal tissue of patients with acute renal injury, minimal change disease, IgA nephropathy, lupus nephritis, and diabetic nephropathy, indicating that CAPG expression may be involved in the occurrence and development of renal fibrosis caused by renal injury. Then, by constructing a CAPG knockout mouse model, it was found that knocking out CAPG can effectively reduce the progression of renal fibrosis. By culturing renal fibroblasts in vitro, it was found that silencing or knocking down CAPG can inhibit TGF-β-induced renal fibroblast activation. The research of the present invention is of great significance for the pathogenesis and treatment of renal injury or renal fibrosis.

A compound for inhibiting C3 gene expression, a pharmaceutical composition and a use thereof, belonging to the technical field of small nucleic acid drug delivery. A compound conjugated with an oligonucleotide and a pharmaceutical composition thereof can significantly inhibit the expression of C3 mRNA in animal liver tissue and C3 protein in serum and can reduce C3 deposition in renal tissue and improve the course of disease featuring C3 deposition in renal tissue. The no-adverse-effect level (NOAEL) in SD rats and cynomolgus monkeys is 300 mg / kg. The compound conjugated with a oligonucleotide and the pharmaceutical composition thereof are helpful in alleviating, preventing and / or treating diseases or conditions mediated by dysregulated C3 gene expression.

The present invention relates to a traditional Chinese medicine composition for treating diabetic nephropathy and a preparation method thereof, belonging to the technical field of traditional Chinese medicine compositions. To solve the problems of single target for western medicine in treating diabetic nephropathy and high risk of adverse reactions when using a combination of multiple drugs, the present invention provides a traditional Chinese medicine composition for treating diabetic nephropathy. The composition formula includes white ginseng, astragalus membranaceus, stir-fried atractylodes macrocephala, poria cocos, chicken gizzard-membrane, kudzu root, wolfberry fruit, Chinese yam, cornel fruit and oriental waterplantain rhizome. The traditional Chinese medicine composition of the present invention has the advantages of multiple components and multiple targets and small adverse reactions. Animal experiments prove that the traditional Chinese medicine composition provided by the present invention can significantly improve the blood glucose, blood lipid, urine protein, creatinine and blood urea nitrogen levels of rats, can significantly improve the pathological changes of the renal tissue of model rats, and can correct the podocyte metabolic pathway and restore its mitochondrial function by specifically increasing the activities of SIRT1 and PGC-1α. It is an effective medicine for treating diabetic nephropathy and provides a new way for the multi-target treatment of clinical diabetic nephropathy.

This invention discloses the application of quinolinic acid in the preparation of drugs for the prevention and treatment of acute kidney injury (AKI). AKI refers to acute kidney injury induced by renal ischemia-reperfusion. The drug is an oral formulation used for prophylactic administration in high-risk individuals undergoing iatrogenic procedures at potential AKI risk, and for pretreatment of ischemic conditions in transplanted kidneys. Experiments have shown that administration of quinolinic acid significantly reduces serum urea nitrogen levels in AKI mice, alleviates renal tissue morphological damage in AKI mice, and reduces the expression level of the renal tubular injury factor NGAL protein in AKI mice, demonstrating significant clinical value in the prevention and treatment of AKI.

Provided are a kidney-targeting delivery ligand, a conjugate, a composition, and a use thereof, relating to the technical field of oligonucleotide drugs. Provided is a delivery ligand suitable for kidney targeting. The delivery ligand and an active substance (such as an oligonucleotide) are covalently linked by means of a linker group to obtain an oligonucleotide conjugate. The oligonucleotide conjugate has affinity for a cell receptor present on a kidney target cell and can selectively and effectively reduce or inhibit the expression of a kidney target gene in a subject (such as human or animal). The provided oligonucleotide conjugate or pharmaceutical composition can effectively treat and / or prevent pathological conditions or diseases caused by aberrant expression of a specific gene in kidney tissue cells.

The invention discloses a 15-antibody combination for accurately detecting a mouse tissue immune cell subset and application of the 15-antibody combination. Aiming at the problems of large fluctuation and instability of detection results caused by adjustment of voltage and fluorescence compensation during detection by a flow cytometer and different processing modes during result analysis, the antibody combination disclosed by the invention takes monoclonal antibodies CD45, CD3, CD4, CD8, CD19, B220, Ly-6C, Ly-6G, MHC-II, CD11c, CD49b, CD62L, CD44 +, PD-1 and PD-L1 as effective components, and a stable and standard detection method for mouse tissue immune cell subsets is established. The method can analyze the proportion, number and distribution of various immune cells (T cells, B cells, NK cells, dendritic cells, mononuclear cells and granulocytes) in spleen, lung, liver, brain or kidney tissues of mice, can reflect the immune state of the mice and evaluate the immunosuppression state, and can be applied to the fields of disease models, drug evaluation, vaccine development and the like.

The invention relates to an application of a succinate dehydrogenase subunit SDHC protein and a coding gene thereof in preparation of a medicine for preventing and / or treating renal fibrosis, and belongs to the field of biological medicines. The invention proposes and verifies that SDHC gene delivery can alleviate kidney pathological changes of chronic kidney diseases for the first time; the expression level of kidney tissue fibrosis related indexes is reduced; the transdifferentiation of renal tubular epithelial cells to myofibroblasts is inhibited. SDHC gene delivery can achieve the effect of improving the chronic kidney disease, and good development and application prospects are achieved.

The invention relates to the technical field of surgical planning, in particular to a kidney tumor accurate resection path planning method and system based on three-dimensional modeling, and the method comprises the following steps: obtaining a kidney tissue tumor surface area, extracting a line segment towards a renal gate direction, extending a direction vector, constructing a passing guide line, and continuing a path to a compression direction; extracting a blood vessel crossing path section, dividing an interference area, adjusting the direction of a turning section, connecting a tumor and a renal gate, and generating a resection path planning result set. According to the method, by constructing a direction line segment set extending along a structure compression trend, advancing a path space trend segment by segment, combining a replacement mechanism of regions with inconsistent directions, depending on density division of crossing edge point segments, defining the distribution position of a traffic limited region, adjusting repeated turning segments through direction lines, and eliminating path fluctuation and turn-back interference, the traffic limited region is determined. The extending direction penetrates through the tumor center and is connected with the starting point path, the path track integrally keeps smooth extension, the space layout is more ordered, and the matching performance of the passing line segment structure is enhanced.

The invention discloses a renal interstitial fibrosis noninvasive grading model construction method and system based on multi-parameter MRI, and belongs to the technical field of medical image processing and artificial intelligence, and the method comprises the steps: S1, collecting multi-parameter MRI data of a renal interstitial fibrosis patient and a healthy contrast; s2, preprocessing the data; s3, performing cortex and medullary segmentation on the preprocessed data, and extracting features of the kidney tissue after segmentation; s4, fusing the extracted features, and constructing a comprehensive feature vector; s5, taking the fused comprehensive feature vector and a corresponding renal tissue pathological grading result as training data, inputting the training data into a deep learning model for training, and establishing a non-invasive grading model related to pathological grading; according to the multi-parameter MRI-based renal interstitial fibrosis non-invasive grading model construction method and system provided by the invention, non-invasive and accurate evaluation of the degree of renal interstitial fibrosis is realized by integrating multi-parameter MRI data and a machine learning algorithm.

The present disclosure provides an oligonucleotide conjugate, which is obtained by covalently linking a kidney-targeting polypeptide as a ligand to an oligonucleotide molecule capable of inhibiting the expression of a target gene via a linker group. The oligonucleotide conjugate has affinity to a cell receptor present on a kidney target cell, and can selectively and effectively reduce or inhibit the expression of a target gene in the kidney of a subject (e.g., a human or an animal). The oligonucleotide conjugate or pharmaceutical composition provided by the present disclosure can effectively treat and / or prevent a pathological condition or disease caused by abnormal expression of a specific gene in kidney tissue cells.

The invention provides a traditional Chinese medicine composition for treating renal proteinuria as well as a preparation method and application thereof, and particularly belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30-60 parts of radix astragali, 10-20 parts of roasted rhizoma atractylodis macrocephalae, 8-16 parts of rhizoma polygoni cuspidati, 8-16 parts of rhizoma alismatis, 10-20 parts of rhizoma smilacis glabrae, 8-16 parts of rhizoma curcumae longae, 8-16 parts of lumbricus, 8-16 parts of silkworm larva, 10-20 parts of herba lysimachiae, 10-20 parts of herba centellae, 10-20 parts of sticktight and 10-20 parts of limonium bicolor. The traditional Chinese medicine composition can effectively relieve proteinuria, protect the renal function and regulate the expression of kidney inflammation macrophages, and particularly has the effects of promoting the expression of anti-inflammatory macrophages, reducing the inflammatory factor level of kidney tissue and inhibiting an inflammation signal channel. The traditional Chinese medicine composition provides a safe and effective medicine for treating proteinuria for patients.

The invention relates to application of mannitol in preparation of drugs for reducing uric acid and / or preventing and treating gout kidney. The mass volume percentage of mannitol is 2-5%, and the mannitol in the concentration range can reduce the serum uric acid level by increasing urine uric acid excretion, reduce the uric acid content of the kidney tissue of a gout patient and reduce the serum urea nitrogen and creatinine content at the same time, so that the kidney tissue is protected. The invention further provides a pharmaceutical composition for reducing uric acid and / or preventing and treating gout kidney, which comprises the following components in percentage by mass volume: 2-5% of mannitol and 0.45-0.9% of sodium chloride. The invention provides new application of mannitol, the mannitol has dual effects of reducing the blood uric acid level and protecting the renal function, and a new treatment choice is provided for gout and gout kidney patients.

The invention belongs to the technical field of intelligent medical treatment and clinical decision, and particularly relates to an idiopathic membranous nephropathy prognosis prediction method and system based on deep learning and a cross-modal attention mechanism. In order to realize accurate prognosis evaluation of IMN, depth features of a kidney tissue pathological image are automatically extracted through a deep learning technology and are innovatively and deeply fused with clinical data of a patient, and finally a high-precision and explainable intelligent prediction model is constructed to guide clinical early intervention and individualized treatment decision.

The invention provides application of dehydrorhynchophylline in preparation of a medicine for reducing toxicity of polymyxin, and belongs to the technical field of medicines. Dehydrorhynchophylline is combined with polymyxin, the activity of HEK293T and RAW264.7 cells is increased to 87.7% and 94.3% through combined use of the dehydrorhynchophylline and the polymyxin E, the difference is extremely remarkable compared with that of a contrast, and it is indicated that when dehydrorhynchophylline and polymyxin E are combined for treatment, the cytotoxic effect of the polymyxin E can be remarkably inhibited. Mouse model research proves that the combined treatment of dehydrorhynchophylline and polymyxin E can significantly reduce the neurotoxicity and renal toxicity of mice caused by single treatment of polymyxin E, specifically, the improvement effect on neurobehavioristics and the improvement on histopathology of brain tissues and kidney tissues. Dehydrorhynchophylline is combined with polymyxin E, so that the cytotoxicity, neurotoxicity and renal toxicity of the polymyxin E can be remarkably inhibited.

The invention discloses application of Dectin-1 as a biomarker in preparation of a renal fibrosis diagnostic reagent or kit, and belongs to the field of biological medicine. And Dectin-1 is a member of a pattern recognition receptor C-type lectin family. According to the invention, Dectin-1 immunofluorescent staining is carried out on kidney tissues of patients with chronic kidney diseases, and observation shows that the number of Dectin-1 + cells in fibrosis kidneys is more. Dectin-1 immunofluorescence staining is further carried out in the kidney tissue of the patient with the IgA nephropathy, and it is found that the number of Dectin-1 + cells in the kidney tissue of the patient with the IgA nephropathy is in positive correlation with the renal fibrosis degree. The results show that the reagent for detecting the expression level of the Dectin-1 in the kidney cells can be used for preparing the kit for diagnosing the kidney fibrosis, and the diagnosis result has high sensitivity and specificity.